Eli Lilly launches once-daily weight-loss pill Foundayo

The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Aurobindo Pharma wins USFDA approval for generic Xigduo XR

Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually

Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity

Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility

Moderna to reveal late-breaking data on flu & RSV mRNA vax at ESCMID 2026

The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21

ImmunityBio responds to FDA concerns over promotional content

Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109

The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved

The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave

As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact